Revolution Medicines

Executive Director, Analytical Development & Quality Control

Redwood City, California, United States · Director · Full-time

Sponsorship not specified$265k-$331kDetected 22 hours ago

ComplianceProduct ManagementGMPFDA RegulatoryLeadershipCommunicationCollaboration

About the role

We are seeking an accomplished and visionary Executive Director, Analytical Development & Quality Control (ADQC) to provide enterprise leadership for analytical development, quality control, and CMC analytical strategy across our expanding oncology portfolio.

Partner cross-functionally to ensure analytical strategies support accelerated development while maintaining scientific rigor, regulatory compliance, and commercial readiness.
Build organizational capability by fostering scientific excellence, innovation, continuous improvement, accountability, collaboration, and inclusion across the ADQC organization.
Foster strategic scientific collaborations with external experts, industry consortia, and technology partners while leveraging emerging analytical technologies and best practices.
Build strategic partnerships that enhance technical capabilities, operational scalability, business continuity, and commercialization readiness.
Develop long-term strategic partnerships that expand analytical capabilities, improve organizational agility, and support commercialization needs.
Collaborate with external partners to drive innovation and accelerate product development while maintaining scientific excellence and compliance.
Experience building analytical/QC functions in a high-growth biotech environment.

PhD (preferred) or MSc in Analytical Chemistry, Pharmaceutical Sciences, or related field.
~18+ years of industry experience with significant leadership in analytical development and QC.
Proven track record supporting late-stage development and global regulatory filings (IND/NDA/MAA/JNDA).
Demonstrated success leading and scaling teams (10+ years in leadership roles preferred).
Deep expertise in GMP, quality systems, and global regulatory expectations (FDA, EMA, ICH).
Extensive experience managing external analytical networks (CDMOs, CTLs).
Strong strategic thinking with the ability to make data-driven, risk-balanced decisions.
Excellent communication and stakeholder influence at executive levels.
Experience in oncology or targeted therapies.
Background in accelerated or expedited development pathways.
Ability to balance speed, quality, and risk in a dynamic setting.
#LI-Hybrid #LI-GL1

$265,000 - $331,000 USD
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process.

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers.
The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.
The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

This listing is sourced directly from Revolution Medicines's careers page and normalized into a canonical job model.